BiotechTube

Tibulizumab Dose A + Tibulizumab Dose B

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hidradenitis Suppurativa (HS)

Conditions

Hidradenitis Suppurativa (HS)

Trial Timeline

May 16, 2025 → Apr 1, 2027

NCT ID
NCT06993610

About Tibulizumab Dose A + Tibulizumab Dose B

Tibulizumab Dose A + Tibulizumab Dose B is a phase 2 stage product being developed by Zura Bio for Hidradenitis Suppurativa (HS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06993610. Target conditions include Hidradenitis Suppurativa (HS).

What happened to similar drugs?

1 of 20 similar drugs in Hidradenitis Suppurativa (HS) were approved

Approved (1) Terminated (0) Active (19)
✅Placebo + AdalimumabAbbVieApproved
🔄SonelokimabMoonLake ImmunotherapeuticsPhase 3
🔄SonelokimabMoonLake ImmunotherapeuticsPhase 3
🔄Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
🔄Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
🔄Lutikizumab + PlaceboAbbViePhase 3
🔄Upadacitinib + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06993610Phase 2Recruiting

Competing Products

20 competing products in Hidradenitis Suppurativa (HS)

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab (M1095) + AdalimumabMoonLake ImmunotherapeuticsPhase 2
29
Eltrekibart + PlaceboEli LillyPhase 2
39
Placebo + LY3041658Eli LillyPhase 2
35
Placebo + AdalimumabAbbVieApproved
43
Lutikizumab + PlaceboAbbViePhase 3
47
AdalimumabAbbViePre-clinical
26
Upadacitinib + PlaceboAbbViePhase 3
47
adalimumab + placeboAbbViePhase 3
40
LutikizumabAbbViePhase 2
42
adalimumabAbbViePhase 3
40
Lutikizumab + PlaceboAbbViePhase 2
39
Risankizumab + Placebo for risankizumabAbbViePhase 2
35
adalimumabAbbViePhase 3
40
adalimumab + placeboAbbViePhase 3
40
Upadacitinib + PlaceboAbbViePhase 2
35
MEDI8968 + SalineAstraZenecaPhase 2
27